- Home
- BKU vs EWTX Comparison
BKU vs EWTX Comparison
Compare BKU & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BKU | EWTX |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | 154 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BKU | EWTX |
|---|---|---|
| Price | $46.22 | $32.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $51.58 | $39.00 |
| AVG Volume (30 Days) | 596.3K | ★ 1.2M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ 14.61 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $21,732,000.00 | N/A |
| Revenue This Year | $16.26 | N/A |
| Revenue Next Year | $4.78 | N/A |
| P/E Ratio | $55.78 | ★ N/A |
| Revenue Growth | ★ 7.45 | N/A |
| 52 Week Low | $33.06 | $12.31 |
| 52 Week High | $52.11 | $39.96 |
Technical Indicators
Market Signals| Indicator | BKU | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.74 | 47.67 |
| Support Level | $44.29 | $27.81 |
| Resistance Level | $47.37 | $35.00 |
| Average True Range (ATR) | 1.07 | 1.69 |
| MACD | -0.07 | -0.27 |
| Stochastic Oscillator | 36.13 | 15.16 |
Price Performance
Historical ComparisonAbout BKU BankUnited Inc.
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses. The company also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products including commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.